Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | USP2 | O75604 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.63 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.63 |
| ▸ | CRHBP | P24387 | 1/20 | 0.63 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NQO2 | P16083 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2461966 | 1.00 | RAB9A (0.69) | RAB9AMEN1KMT2ANPC1USP2 | |
| SCHEMBL30869156 | 0.94 | MEN1 (0.71) | RAB9AMEN1KMT2ANPC1USP2 | |
| SCHEMBL10489040 | 0.90 | CYP2A6 (0.69) | RAB9AMEN1KMT2ANPC1USP2 | |
| SCHEMBL2604943 | 0.89 | MEN1 (0.60) | RAB9AMEN1KMT2ANPC1USP2 | |
| SCHEMBL18160195 | 0.86 | MEN1 (0.61) | RAB9AMEN1KMT2ANPC1USP2 | |
| SCHEMBL20921497 | 0.86 | MEN1 (0.61) | RAB9AMEN1KMT2ANPC1USP2 | |
| SCHEMBL29506661 | 0.86 | MEN1 (0.66) | RAB9AMEN1KMT2ANPC1USP2 | |
| SCHEMBL18666459 | 0.86 | MEN1 (0.61) | RAB9AMEN1KMT2ANPC1USP2 | |
| SCHEMBL18160296 | 0.86 | MEN1 (0.66) | RAB9AMEN1KMT2ANPC1USP2 | |
| SCHEMBL3151185 | 0.86 | MEN1 (0.61) | RAB9AMEN1KMT2ANPC1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117925097-A | Environment-friendly aggregation-induced emission flame-retardant coating and preparation method thereof | 天津市职业大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-10-03 | — | — | US | disclosed |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-02 | — | — | US | disclosed |
| WO-2015154169-A1 | BINDING FUNCTION3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-10-15 | — | — | WO | disclosed |
| US-8158380-B2 | Imaging agents for protein misfolding | NEW YORK UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158380-B2 | Imaging agents for protein misfolding | NEW YORK UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110237633-A1 | SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-09-29 | — | — | US | disclosed |
| US-20100279340-A1 | Imaging agents for protein misfolding | NYU (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279340-A1 | Imaging agents for protein misfolding | NYU (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2010068287-A2 | SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279340-A1 | Imaging agents for protein misfolding | APBA1, APP, SPG11 | RAB9A 1876/4885MEN1 2123/4885KMT2A 3853/4885 |
| US-20110237633-A1 | SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | HGF, HDGF, MET | RAB9A 3044/4885MEN1 2613/4885KMT2A 4354/4885 |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | RAB9A 2978/4885MEN1 681/4885KMT2A 4323/4885 |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | RAB9A 2978/4885MEN1 681/4885KMT2A 4323/4885 |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | RAB9A 2978/4885MEN1 681/4885KMT2A 4323/4885 |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | RAB9A 2978/4885MEN1 681/4885KMT2A 4323/4885 |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | RAB9A 2978/4885MEN1 681/4885KMT2A 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.